This image provided by Sarepta Therapeutics in December 2019 shows a box and vial of their drug Vyondys 53. On Thursday, Dec. 12, 2019, U.S. health regulators said they approved this second drug for a debilitating form of muscular dystrophy, a surprise decision after the medication was rejected for safety concerns just four months earlier. (Sarepta Therapeutics via AP)
Featured Photo Galleries
Trump Transition: Here are the people Trump has picked for key positions so far
President-elect Donald Trump has announced a flurry of picks for his incoming administration. Get full coverage of the Trump transition from The Washingon Times.
Trump dances onstage, takes post-election nation by storm
President-elect Trump dances onstage
